Showing results (81-90 of 116) with videos related to

Sort By:
Pageof 12
ESMO Open|February 3, 2026
Incidence and risk factors of brain metastases in radically resected melanoma patients: a large international cohort studyM Mandalà, P Rutkowski, R Patuzzo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 29, 2014
Patient perception of the benefit of a BRAF inhibitor in metastatic melanoma: quality-of-life analyses of the BREAK-3 study comparing dabrafenib with dacarbazineJ-J Grob, M M Amonkar, S Martin-Algarra, et al.
Translational Psychiatry|February 18, 2022
Metabolic effects of the schizophrenia-associated 3q29 deletionRebecca M Pollak, Ryan H Purcell, Timothy P Rutkowski, et al.
ESMO Open|June 19, 2022
Systemic treatment of advanced clear cell sarcoma: results from a retrospective international series from the World Sarcoma NetworkA Smrke, A M Frezza, C Giani, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 10, 2016
Prospective assessment of a gene signature potentially predictive of clinical benefit in metastatic melanoma patients following MAGE-A3 immunotherapeutic (PREDICT)P Saiag, R Gutzmer, P A Ascierto, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 27, 2023
Circulating tumor DNA analysis of the phase III VOYAGER trial: KIT mutational landscape and outcomes in patients with advanced gastrointestinal stromal tumor treated with avapritinib or regorafenibC Serrano, S Bauer, D Gómez-Peregrina, et al.
British Journal of Cancer|August 24, 2013
MiR-17-92 and miR-221/222 cluster members target KIT and ETV1 in human gastrointestinal stromal tumoursC M M Gits, P F van Kuijk, M B E Jonkers, et al.
European Journal of Cancer (Oxford, England : 1990)|November 13, 2013
Brostallicin versus doxorubicin as first-line chemotherapy in patients with advanced or metastatic soft tissue sarcoma: an European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group randomised phase II and pharmacogenetic studyH Gelderblom, J Y Blay, B M Seddon, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 4, 2023
Overall survival from tebentafusp versus nivolumab plus ipilimumab in first-line metastatic uveal melanoma: a propensity score-weighted analysisJ M Piulats, C Watkins, M Costa-García, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 8, 2014
Functional and symptom impact of trametinib versus chemotherapy in BRAF V600E advanced or metastatic melanoma: quality-of-life analyses of the METRIC studyD Schadendorf, M M Amonkar, M Milhem, et al.
Pageof 12